ALGS Q2 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$965,000-9.0% YoY

Gross Profit

$706,00073.2% margin

Operating Income

-$19M-1924.0% margin

Net Income

-$16M-1643.8% margin

EPS (Diluted)

$-1.53

QoQ Revenue Growth

+210.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$135M

Total Liabilities

$33M

Stockholders' Equity

$102M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$965,000	$1M	-9.0%
Gross Profit	$706,000	$451,000	+56.5%
Operating Income	-$19M	-$26M	+29.7%
Net Income	-$16M	$5M	-413.4%